Navigation Links
Virginia Commonwealth University findings may help explain high blood pressure in pregnancy
Date:10/31/2011

RICHMOND, Va. -- Virginia Commonwealth University School of Medicine researchers have discovered that the infiltration of white blood cells into an expectant mother's blood vessels may explain high blood pressure in pregnancy.

The findings could lead to novel avenues of treatment for pregnant women with preeclampsia based on regulation of white blood cells called neutrophilis, their products or their cellular effects.

Preeclampsia is one of the most significant health problems in pregnancy and a leading cause worldwide of both premature delivery and of sickness and death of the mother and baby. Research has shown that the blood vessels of women with preeclampsia are dysfunctional, but the cause of preeclampsia is not known, and the only treatment is delivery of the baby.

In a study published online in the October issue of Hypertension, a journal of the American Heart Association, the VCU team reported that an infiltration of white blood cells may be responsible for the high blood pressure observed in preeclampsia. These white blood cells release reactive oxygen species that the team showed enhance the reactivity of the mother's blood vessels to hypertensive hormones by activating the RhoA kinase pathway in the blood vessels. Read the study here.

According to corresponding author Scott W. Walsh, Ph.D., professor in the VCU Department of Obstetrics and Gynecology, the RhoA kinase pathway is an intracellular mechanism in the smooth muscle cells of blood vessels that makes the blood vessels more reactive to hormones that increase blood pressure.

"In other words, the blood vessels contract more easily to the hormones so blood pressure increases even though the hormone levels do not increase," said Walsh.

"These findings may explain the enhanced blood pressure response of women who develop preeclampsia, which was first described almost 40 years ago," he said.

Walsh said some potential treatments on the horizon for clinical studies are monoclonal antibodies that could prevent the infiltration of the white blood cells, and selective RhoA kinase inhibitors that could prevent the enhanced reactivity of the mother's blood vessels.


'/>"/>
Contact: Sathya Achia Abraham
sbachia@vcu.edu
804-827-0890
Virginia Commonwealth University
Source:Eurekalert

Related medicine news :

1. Virginia Commonwealth University study: We are what we experience
2. TGen/Virginia G. Piper Cancer Center publish results of new drug for pancreatic cancer patients
3. TGen-Virginia G. Piper Cancer Center launches clinical trial for drug to treat lung cancer
4. Months After Shootings, Many Virginia Tech Students Suffered PTSD
5. TGen, Virginia G. Piper Cancer Center studying new breast cancer drug
6. VCU Massey Cancer Center awarded $2.4 million grant from Virginia Tobacco Commission
7. Virginia Bioinformatics Institute to model immune responses to gut pathogens
8. Virginia Tech professor discovers new TB pathogen
9. VCU first Virginia institution to join national network of academic research centers
10. Dr. Phillip Chang Introduces New Ways to Decrease Scars and Potential Complications For Breast Augmentations in Loudoun and Fairfax Virginia
11. Virginia Hospital Shared Services Corporation Selects Verified Credentials as its Exclusively Endorsed Provider of Background Screening Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... February 08, 2016 , ... FileHold's document management software ... provides a cloud hosted environment for FileHold software that is pay per user ... party applications using the FileHold web services API. DocuSyst also advises clients on ...
(Date:2/8/2016)... ... 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to a product ... from a cluster of melanin when exposed to sunlight. Although most moles are benign ... of embarrassment. Historically, mole removal has involved a painful, often expensive visit ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... four states in the U.S. require dental technicians to be certified or obtain ... dental industry, NADL created the “What’s In Your Mouth?” campaign to inform dentists ...
(Date:2/7/2016)... ... February 07, 2016 , ... Dr. Todd ... to his medical and surgical expertise. Technically known as deoxycholic acid or previously ... as a non-surgical alternative for reduction of fat below the chin (aka the ...
(Date:2/6/2016)... ... February 06, 2016 , ... Shark Finds and Kevin Harrington, along ... new DRTV campaign with Belly Bands. , Having a dog is great—except when it ... pads and find nothing works, get Belly Bands, the easiest way to stop ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... http://www.researchandmarkets.com/research/bcrl3s/labelfree ) ... "Label-Free Detection Market by Technology, Products, Applications ... to their offering. --> http://www.researchandmarkets.com/research/bcrl3s/labelfree ... "Label-Free Detection Market by Technology, Products, ... report to their offering. --> ...
(Date:2/8/2016)... 8, 2016  Astellas Pharma Inc. President and Chief Executive ... James Robinson as president, Americas Operations, for Astellas ... and South America , effective April 1, ... the commercial organization in the United States ... Masao Yoshida , who is retiring in June 2016.  ...
(Date:2/8/2016)... 2016  LivaNova, PLC, Hersteller des VNS-Therapie ... dem Titel „Epilepsy Around the World" (Epilepsie ... Krankheit gegenüber ein größeres Bewusstsein gefördert werden ... bei Epilepsie auf dem Internationalen Epilepsietag zu ... Mithilfe der neuen Infografik sollen wichtige Statistiken ...
Breaking Medicine Technology: